Trial Profile
A phase-II trial of ZIO 101 [darinaparsin] in advanced hepatocellular carcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Alaunos Therapeutics
- 13 Nov 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned end date changed from 1 Dec 2008 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.